Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aybar Ecotechnologies Corp. is addressing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is centralized under 1 distinct examiner and 1 distinct art unit, reflecting a very focused administrative footprint. This alignment suggests that the company's current patent efforts are concentrated on a specific technical advancement within the biotech sector.
The busiest examiner for the portfolio is DABKOWSKI, ERINNE R, who has 1 pending office action. This examiner is the sole official currently reviewing the company's pending applications. Because the entirety of the company's active prosecution is in the hands of DABKOWSKI, ERINNE R, the outcome of this single matter will define the company's immediate success at the USPTO.
The presence of only 1 pending office action indicates a relatively low volume of active prosecution for the company. While this minimizes the complexity of managing multiple deadlines, it also means that the company's patent strategy is currently highly dependent on the results of this specific case. Practitioners should focus on the specific examination history of the assigned examiner to optimize the response strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18505472 | WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAME | DABKOWSKI, ERINNE R | 15d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18505472 | WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAME | DABKOWSKI, ERINNE R | 15d |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18505472 | WIDE-SPECTRUM ANTIBACTERIAL PHARMACEUTICAL FORMULATIONS COMPRISING LYSOZYME AND METHODS OF USING THE SAME | DABKOWSKI, ERINNE R | 1654 | §102§103§112 | Final Rejection | 15d | Pending | Nov 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial